ARLN and breast cancer: Even though there are clinical trials indicating that IMLN metastasis does not independently predict overall survival and progression-free survival for BC patients who receive personalized adjuvant treatment, internal mammary lymph node invasion has been observed in up to 52% of ALN-positive patients and in up to 17% of ALN-negative patients [39, 40].